ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma

by Matthew Kennedy, Benzinga Staff Writer
September 22, 2011 4:02 PM | 10 seconds read |
ImmunoGen, Inc. IMGN, today announced its submission of the Investigational New Drug (IND) application for its IMGN529 product candidate to the U.S. Food and Drug Administration.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!